RCT of Adjunctive Curcumin and the Meru Health Program

Launched by MERU HEALTH, INC. · Feb 3, 2021

Keywords

ClinConnect Summary

This is a randomized controlled trial (RCT) to compare the Meru Health Program plus adjunctive curcumin (MHP-CUR) versus Meru Health Program only (MHP-ONLY) for adults with depression. Meru Health is a 12-week integrative treatment program based on several evidence-based practices and overseen by licensed clinical therapists that is delivered via a Smartphone app. The primary objective of the study is to determine the feasibility, initial efficacy (depressive symptoms), and potential harms of taking adjunctive curcumin supplementation during the 12-week MHP among adults with depression. Sec...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • Patient presenting to the Meru Health online clinic
• • Able to read and understand English
• • Own a Smartphone
• • Willing to commit to doing program practices for 10 minutes a day, 6 days a week for 12 weeks
• • PHQ-9 of 10 or higher
• Exclusion Criteria:
• • Lifetime bipolar disorder or a psychotic disorder
• • Possible cognitive impairment
• • Substance use disorder in the past 3 months
• • Active suicidal ideation with at least some intent to act
• • Pregnant, breastfeeding, or desiring to become pregnant in the next 6 months
• • Self-reported current suffering from a major medical illness including neurodegenerative/neuroinflammatory disorders, anemia, Alzheimer's disease, stroke, Parkinson's disease, or multiple sclerosis, autoimmune disorders, diabetes, inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, coagulation disorder, cardiovascular disease, hypertension, chronic fatigue syndrome, fibromyalgia
• • Self-reported current use of glucocorticoids, antibiotics, anticoagulant medications, antioxidant supplements (including curcumin), herbal supplements, or ω3 polyunsaturated fatty acids
• • Self-reported past suffering from an infection or illness over the past month